Related Experiment Video

Updated: May 24, 2026

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term

E Ozkaya1, E Çakır, S Uzuner

  • 1Department of Pediatrics, Division of Pediatric Allergy, Bezmialem Vakif University, Istanbul, Turkey. minozkaya@yahoo.com

Allergologia Et Immunopathologia
|March 13, 2012
PubMed

Insights

Long-term use of inhaled fluticasone propionate in children with asthma does not negatively impact bone mineral density. This study found no significant differences in bone mineral density (BMD) between treated children and controls.

Area of Science:

  • Pediatric Pulmonology
  • Endocrinology
  • Pharmacology

Background:

  • Inhaled corticosteroids are a cornerstone of asthma management in children.
  • Concerns exist regarding potential long-term effects of corticosteroid therapy on bone health.

Purpose of the Study:

  • To evaluate the impact of prolonged inhaled fluticasone propionate use on bone mineral status in pediatric asthma patients.
  • To assess bone mineral density (BMD) in children with asthma treated with inhaled fluticasone propionate for at least five years.

Main Methods:

  • A cross-sectional, case-control study involving 270 pre-pubertal children with asthma on inhaled fluticasone propionate (mean daily dose 200 μg for ≥5 years).
  • Bone mineral density (BMD) of the lumbar spine was measured using dual-energy X-ray absorptiometry (DEXA).
  • Results were compared to 200 newly diagnosed, untreated children with asthma.

Main Results:

  • No statistically significant difference in BMD was observed between the group treated with inhaled fluticasone propionate and the untreated control group (p>0.05).
  • The study included 270 children aged 6-13 years, with a mean daily steroid dosage of 183.3±57.0 μg.

Conclusions:

  • Long-term (5-year) treatment with inhaled fluticasone propionate at a recommended dose (100 μg twice daily) does not adversely affect bone mineral density in children with asthma.
  • DEXA measurements indicate that inhaled fluticasone propionate is safe for bone health in pediatric asthma patients when used as prescribed.
Abstract

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Related Concept Videos

Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...